Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis
Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary or Key Secondary Endpoints Cytokinetics to Host Conference Call and... | March 31, 2023